| Methods |
Randomized
Multicenter |
| Participants |
Age > 65 or 18 to 65 years + comorbidities (mean age: 68.5)
Severe CAP: exclusion: "risk of death within 48h of study start"
Hospitalized |
| Interventions |
Atypical: IV teicoplanin 400 mg LD, followed by 400/200 mg X 1/d (per investigator's discretion) + PO ciprofloxacin 500 mg X 2/d
Non‐atypical: IV ceftriaxone 2 G X 1/d |
| Outcomes |
Clinical response: success (cure, improvement), failure and data could not be evaluated |
| Notes |
Severe CAP; elderly or comorbidities
Allegra 1995 is a double publication of this study |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Not described |
| Allocation concealment (selection bias) |
Unclear risk |
Not described |
| Incomplete outcome data (attrition bias)
Mortality |
High risk |
225/240 patients evaluated |
| Incomplete outcome data (attrition bias)
Failure |
High risk |
225/240 patients evaluated |
| Selective reporting (reporting bias) |
Low risk |
Not identified |
| Other bias |
Unclear risk |
Sponsored |
| Blinding of participants and personnel (performance bias)
All outcomes |
High risk |
None |
| Blinding of outcome assessment (detection bias)
All outcomes |
High risk |
None |
